Skip to main content

Verona Pharma plc

VRNADelisted Oct 7, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001657312

Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Verona Pharma plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Verona Pharma plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Verona Pharma plc
NameTitleLast reported holdingLast filingFilings, past year
Ebsworth David RDirector0IndirectOct 8, 20251
Shah MahendraDirector0Oct 8, 20251
Sinha VikasDirector0Oct 8, 20251
Hahn Mark WChief Financial Officer0Oct 8, 20251
Zaccardelli DavidPresident and CEO0Oct 8, 20251
Edwards MartinDirector0Oct 8, 20251
Ackermann ChristinaDirector0Oct 8, 20251
Ullman AndersDirector0Oct 8, 20251
Cunningham KennethDirector0Oct 8, 20251
Rickard Kathleen A.Chief Medical Officer0Oct 8, 20251
Deschamps LisaDirector0Oct 8, 20251
Brady James AloysiusDirector0Oct 8, 20251
Austwick MichaelDirector0Oct 8, 20251
Fisher AndrewGeneral Counsel0Oct 8, 20251
Poll ClaireGeneral Counsel1,176,920IndirectFeb 5, 20240
OrbiMed Advisors LLCDirector3,777,778IndirectMay 15, 20230
OrbiMed Capital GP VI LLCDirector3,777,778IndirectMay 15, 20230
Gupta RishiDirector3,777,778IndirectMay 15, 20230
Blavatnik Len10% Owner55,911,648IndirectAug 17, 20220
Access Industries Holdings LLC10% Owner55,911,648IndirectAug 17, 20220
Access Industries Management, LLC10% Owner55,911,648IndirectAug 17, 20220
AI Biotechnology LLC10% Owner55,911,648IndirectAug 17, 20220
Sinclair AndrewDirector–Aug 10, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 3, 2021 (view filing)Aug 21 dayHahn Mark WChief Financial OfficerSSale−10.4K$0.77−$8.02K−0.1%16.5M after
Aug 4, 2021 (view filing)Aug 3-41 dayZaccardelli DavidPresident and CEOSSale−34.4K$0.7493−$25.8K−0.2%17.4M after2 lots
Aug 9, 2021 (view filing)Aug 36 daysLateZaccardelli DavidPresident and CEOSSale−17.7K$0.75−$13.2K−0.1%17.4M after
Nov 3, 2021 (view filing)Nov 21 dayHahn Mark WChief Financial OfficerSSale−10.4K$0.65−$6.77K−0.1%16.0M after
Nov 3, 2021 (view filing)Nov 21 dayZaccardelli DavidPresident and CEOSSale−52.1K$0.64−$33.3K−0.3%16.8M after
Nov 3, 2021 (view filing)Nov 21 dayDeschamps LisaDirectorSSale−11.7K$0.66−$7.70K−12.5%82.0K after
Feb 3, 2022 (view filing)Feb 21 dayHahn Mark WChief Financial OfficerSSale−10.4K$0.76−$7.92K−0.1%15.8M after
Feb 3, 2022 (view filing)Feb 3Same dayZaccardelli DavidPresident and CEOSSale−52.1K$0.73−$38.0K−0.3%16.8M after
Feb 3, 2022 (view filing)Feb 12 daysDeschamps LisaDirectorSSale−11.7K$0.78−$9.10K−14.2%70.3K after
Apr 12, 2022 (view filing)Apr 8-114 daysRickard Kathleen A.Chief Medical OfficerSSale−172.5K$0.5727−$98.8K−6.3%2.55M after2 lots
May 5, 2022 (view filing)May 32 daysHahn Mark WChief Financial OfficerSSale−12.5K$0.50−$6.26K−0.1%15.4M after
May 5, 2022 (view filing)May 32 daysZaccardelli DavidPresident and CEOSSale−32.9K$0.50−$16.5K−0.2%16.4M after
May 5, 2022 (view filing)7:19 PM ETMay 32 daysRickard Kathleen A.Chief Medical OfficerSSale−28.8K$0.4923−$14.2K−1.2%2.46M after
Aug 3, 2022 (view filing)Aug 12 daysHahn Mark WChief Financial OfficerSSale−13.2K$0.70−$9.22K−0.1%14.9M after
Aug 3, 2022 (view filing)Aug 21 dayRickard Kathleen A.Chief Medical OfficerSSale−28.8K$0.70−$20.1K−1.2%2.38M after
Aug 3, 2022 (view filing)Aug 12 daysZaccardelli DavidPresident and CEOSSale−32.9K$0.70−$23.0K−0.2%15.9M after
Aug 11, 2022 (view filing)Aug 92 daysHahn Mark WChief Financial OfficerSSale−600.0K$1.75−$1.05M−4.0%14.3M after
Aug 11, 2022 (view filing)Aug 92 daysZaccardelli DavidPresident and CEOSSale−600.0K$1.75−$1.05M−3.8%15.3M after
Aug 17, 2022 (view filing)4:03 PM ETAug 152 daysBlavatnik Len and 3 others10% OwnerPPurchase+4.80M$1.31+$6.30M+9.4%55.9M after
Nov 3, 2022 (view filing)Nov 12 daysHahn Mark WChief Financial OfficerSSale−13.2K$1.67−$22.0K−0.1%17.4M after
Nov 3, 2022 (view filing)Nov 12 daysRickard Kathleen A.Chief Medical OfficerSSale−28.8K$1.64−$47.2K−0.9%3.09M after
Nov 3, 2022 (view filing)Nov 12 daysZaccardelli DavidPresident and CEOSSale−32.9K$1.67−$54.9K−0.2%18.4M after
Dec 21, 2022 (view filing)Dec 201 dayHahn Mark WChief Financial OfficerSSale−600.0K$2.12−$1.27M−3.4%16.8M after
Dec 21, 2022 (view filing)Dec 201 dayZaccardelli DavidPresident and CEOSSale−600.0K$2.12−$1.27M−3.3%17.8M after
Dec 27, 2022 (view filing)Dec 22-235 daysGupta RishiDirectorSSale−6.14M$22.15−$136.0M−15.3%34.1M after5 lots
Dec 27, 2022 (view filing)Dec 225 daysPoll ClaireGeneral CounselSSale−240.0K$2.69−$645.6K−23.7%774.3K after
Dec 27, 2022 (view filing)5:38 PM ETDec 22-235 daysOrbiMed Advisors LLC and 1 otherDirectorSSale−6.14M$22.15−$136.0M−15.3%34.1M after5 lotsDuplicate filing
Feb 3, 2023 (view filing)Feb 12 daysPoll ClaireGeneral CounselSSale−152.0K$2.59−$393.7K−16.4%774.3K after
Feb 3, 2023 (view filing)Feb 1-22 daysRickard Kathleen A.Chief Medical OfficerSSale−118.7K$2.55−$303.0K−3.7%3.08M after2 lots
Feb 3, 2023 (view filing)Feb 12 daysZaccardelli DavidPresident and CEOSSale−432.9K$2.56−$1.11M−2.4%17.3M after
Feb 3, 2023 (view filing)Feb 12 daysHahn Mark WChief Financial OfficerSSale−413.2K$2.56−$1.06M−2.5%16.4M after
May 3, 2023 (view filing)May 12 daysZaccardelli DavidPresident and CEOSSale−455.5K$2.58−$1.18M−2.6%16.9M after10b5-1
May 3, 2023 (view filing)May 12 daysHahn Mark WChief Financial OfficerSSale−455.5K$2.58−$1.18M−2.8%16.0M after10b5-1
May 15, 2023 (view filing)May 11-154 daysGupta RishiDirectorSSale−482.9K$20.58−$9.94M−11.3%3.78M after4 lots
May 15, 2023 (view filing)6:07 PM ETMay 11-154 daysOrbiMed Advisors LLC and 1 otherDirectorSSale−482.9K$20.58−$9.94M−11.3%3.78M after4 lotsDuplicate filing
Aug 3, 2023 (view filing)Aug 1-22 daysRickard Kathleen A.Chief Medical OfficerSSale−33.5K$2.64−$88.4K−1.1%2.95M after2 lots10b5-1
Aug 3, 2023 (view filing)Aug 1-22 daysZaccardelli DavidPresident and CEOSSale−179.6K$2.64−$474.8K−1.1%16.7M after2 lots10b5-1
Aug 3, 2023 (view filing)Aug 1-22 daysPoll ClaireGeneral CounselSSale−31.6K$2.64−$83.4K−1.6%1.96M after2 lots10b5-1
Aug 3, 2023 (view filing)Aug 1-22 daysHahn Mark WChief Financial OfficerSSale−179.6K$2.64−$474.8K−1.1%15.8M after2 lots10b5-1
Aug 7, 2023 (view filing)Aug 3-74 daysPoll ClaireGeneral CounselSSale−48.5K$2.52−$122.0K−2.5%1.91M after3 lots10b5-1
Aug 7, 2023 (view filing)Aug 3-74 daysHahn Mark WChief Financial OfficerSSale−275.9K$2.52−$694.2K−1.7%15.5M after3 lots10b5-1
Aug 7, 2023 (view filing)Aug 3-74 daysZaccardelli DavidPresident and CEOSSale−275.9K$2.52−$694.2K−1.7%16.4M after3 lots10b5-1
Aug 7, 2023 (view filing)Aug 3-74 daysRickard Kathleen A.Chief Medical OfficerSSale−80.1K$2.53−$202.6K−2.7%2.87M after4 lots10b5-1
Nov 3, 2023 (view filing)Nov 3Same dayRickard Kathleen A.Chief Medical OfficerSSale−58.8K$1.92−$112.8K−2.0%2.84M after10b5-1
Nov 8, 2023 (view filing)Nov 62 daysEbsworth David RDirectorPPurchase+160.0K$1.98+$316.8K+23.4%844.6K after
Nov 22, 2023 (view filing)Nov 202 daysEdwards MartinDirectorPPurchase+33.7K$1.84+$62.1K+30.4%144.8K after
Feb 5, 2024 (view filing)Feb 5Same dayRickard Kathleen A.Chief Medical OfficerSSale−36.2K$2.22−$80.5K−1.3%2.73M after10b5-1
May 3, 2024 (view filing)May 3Same dayRickard Kathleen A.Chief Medical OfficerSSale−36.2K$1.96−$71.0K−1.4%2.62M after10b5-1
Aug 14, 2024 (view filing)Aug 122 daysEbsworth David RDirectorPPurchase+36.0K$2.87+$103.3K+4.3%880.6K after
Aug 14, 2024 (view filing)Aug 12-132 daysHahn Mark WChief Financial OfficerSSale−400.0K$3.20−$1.28M−2.6%14.9M after3 lots10b5-1